Citations 2
Pediatric Hodgkin Lymphoma, Version 3.2021
Hiniker, Susan M. , Benya, Ellen C. , Bobbey, Adam J. , Cooper, Stacy , Cuglievan, Branko , Isenalumhe, Leidy , Kelly, Kara M. , Kersun, Leslie S. , Lamble, Adam J. , Larrier, Nicole, Magee, J.Fergall, Oduro, Kwadwo A. , Pacheco, Martha, Roberts, Kenneth B. , Smith, Christine M. , Sohani, Aliyah R. , Trovillion, Erin , Walling, Emily , Burns, Jennifer L. , Campbell, Mallory, Smith, Christine M , Flerlage, Jamie E. , Armenian, Saro H. , Chang, Vivian Y. , Coulter, Donald W. , Hoppe, Bradford S. , Magee, Jeffrey, Price, Anita P. , Xavier, Ana C
Journal of the National Comprehensive Cancer Network | November 24, 2021 | Volume: 19 | Issue: 6 | Pages: 733-754
Hodgkin lymphoma (HL) is a highly curable form of cancer, and current treatment regimens are focused on improving treatment efficacy while decreasing the risk of late effects of treatment. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric HL provide recommendations on the workup, diagnostic evaluation, and treatment of classic HL, including principles of pathology, imaging, staging, systemic therapy, and radiation therapy. This portion of the NCCN Guidelines focuses on the management of pediatric classic HL in the upfront and relapsed/refractory settings.
Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Brown, Patrick A. , Inaba, Hiroto , Annesley, Colleen , Beck, Jill C., Colace, Susan I. , Dallas, Mari , Kelly, Kara M. , Larrier, Nicole, Mahadeo, Kris M. , Nanda, Ronica H. , Nardi, Valentina , Rodriguez, Vilmarie , Rossoff, Jenna , Schuettpelz, Laura G. , Sun, Jessica , Sun, Weili, Teachey, David T. , Wong, Victor , Yanik, Gregory A. , Johnson-Chilla, Alyse, Ogba, Ndiya , Inaba, Hiroto , DeSantes, Kenneth B , Kitko, Carrie L. , Lacayo, Norman James , Maese, Luke Devon , Silverman, Lewis B.
Journal of the National Comprehensive Cancer Network | January 7, 2020 | Volume: 18 | Issue: 1 | Pages: 81-112
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.